Vyant Bio, Inc. (VYNT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cherry Hill, NJ, アメリカ. 現CEOは Andrew D.C. LaFrence CPA.
VYNT を有する IPO日 2021-04-01, 4 名の正社員, に上場 NASDAQ Capital Marke.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
